BioCentury
ARTICLE | Clinical News

BMS reports CheckMate -142 data for Opdivo plus Yervoy in dMMR or MSI-H metastatic CRC

January 26, 2018 8:21 AM UTC

Bristol-Myers Squibb Co. (NYSE:BMY) said Opdivo nivolumab plus Yervoy ipilimumab led to an objective response rate (ORR) of 55% among 119 patients with mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer (CRC) in the Phase II CheckMate -142 trial. Data were presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium in San Francisco and published in the Journal of Clinical Oncology.

In the open-label, international trial, 3 mg/kg IV Opdivo plus 1 mg/kg IV Yervoy every three weeks for four doses followed by 3 mg/kg IV Opdivo every two weeks led to 4 complete responses and 61 partial responses, plus 37 cases of stable disease at a median follow-up of 13.4 months per investigator assessment. The ORR per a blinded independent central review was 49%, including a 4% complete response rate and a 45% partial response rate. Median time to response was 2.8 months; median duration of response was not reached. The nine-month progression-free survival (PFS) and overall survival (OS) rates were 76% and 87%, respectively. The 12-month PFS and OS rates were 71% and 85%, respectively...